TVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Travere Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $0.97.
During the past 12 months, Travere Therapeutics's average Book Value Per Share Growth Rate was -61.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -13.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -27.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Travere Therapeutics was -2.20% per year. The lowest was -49.30% per year. And the median was -14.30% per year.
Travere Therapeutics's current price is $6.70. Its book value per share for the quarter that ended in Mar. 2024 was $0.97. Hence, today's PB Ratio of Travere Therapeutics is 6.89.
During the past 13 years, the highest P/B Ratio of Travere Therapeutics was 333.66. The lowest was 1.50. And the median was 3.20.
The historical data trend for Travere Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Book Value per Share | Get a 7-Day Free Trial | 5.13 | 4.04 | 4.83 | 0.67 | 2.66 |
Travere Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Book Value per Share | Get a 7-Day Free Trial | 2.54 | 1.55 | 3.73 | 2.66 | 0.97 |
For the Biotechnology subindustry, Travere Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's PB Ratio falls into.
Travere Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (200.8 | - | 0.0) | / | 75.4 | |
= | 2.66 |
Travere Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (74.1 | - | 0.0) | / | 76.1 | |
= | 0.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Travere Therapeutics (NAS:TVTX) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Travere Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Jula Inrig | officer: Chief Medical Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Peter Heerma | officer: Chief Commercial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
William E. Rote | officer: Senior Vice President, R&D | C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Christopher R. Cline | officer: Chief Financial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130 |
Eric M Dube | director, officer: Chief Executive Officer | 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Elizabeth E Reed | officer: SVP, GC & Corporate Secretary | 9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
Sandra Calvin | officer: VP, Corp Controller and CAO | 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Laura Clague | officer: Chief Financial Officer | 370 PARK RANCH PLACE, ESCONDIDO CA 92025 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Brinkley Ruth Williams | director | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Noah L. Rosenberg | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Neil F. Mcfarlane | officer: Chief Operating Officer | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Sandra Poole | director | 830 WINTER STREET, WALTHAM MA 02451 |
Ron Squarer | director | C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066 |
From GuruFocus
By Marketwired • 08-03-2023
By Marketwired • 08-14-2023
By PRNewswire • 06-30-2023
By PRNewswire • 06-28-2023
By sperokesalga sperokesalga • 06-08-2023
By PRNewswire PRNewswire • 06-21-2023
By Marketwired • 09-11-2023
By Marketwired • 09-21-2023
By sperokesalga sperokesalga • 06-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.